Skip to content
OpenCapital
Get started

Zoetis ZTS Other pharmaceutical — Revenue

Other product segments

Horses
$5.8B+13.9%
Dogs and Cats
$1.35B+11.6%
Parasiticides
$586M+2.4%
Vaccines
$519M+18.2%
Cattle
$399M-0.5%
Dermatology
$349M-7.9%
Anti-infectives
$241M+1.3%
Pain and sedation
$203M-1.9%
Swine
$128M-7.9%
Animal health diagnostics
$117M+12.5%
Poultry
$117M-7.9%
Other Non Pharmaceuticals
$66M-7.0%
Fish
$65M+4.8%
Contract manufacturing & human health
$23M-23.3%
Sheep and other
$17M+6.3%

Similar metrics at other companies

HWK
HWKNPharmaceutical — Revenue
$8.32M+15.1%
Veracyte logo
VCYTBiopharmaceutical and other revenue — Total Revenue
$301K-91.6%
Kiniksa Pharmaceuticals International, plc logo
KNSAPharmaceutical — Revenue
$214.27M+55.5%
AMP
AMPHPharmaceutical Products — Revenue
$171.17M+0.4%
Regeneron Pharmaceuticals logo
REGNOther products — Revenue
$31.3M—
Bristol-Myers Squibb logo
BMYOther revenues — Total Revenues
$227M0.0%

Other financials

Income statement

See full
Revenue$2.3B+2.9%
Gross profit$1.6B+2.6%
Net income$601.0M-0.2%
EPS (diluted)$1.42+6.0%

Balance sheet

See full
Cash & equivalents$1.9B+8.9%
Total debt$10.0B+48.0%
Total equity$3.2B-30.5%
Total assets$15.2B+7.5%

Cash flow

See full
Operating cash flow$401.0M-22.1%
CapEx$110.0M-38.2%
Free cash flow$291.0M-13.6%

Valuation

See full
Market cap$31.9B-54.6%
Enterprise value$39.95B-47.2%
P/E12.1×-15.1×
P/S3.4×-4.1×

Profitability

See full
Gross margin71.8%+0.8pp
Net margin27.8%+0.9pp
FCF margin23.5%0.0pp

Returns & leverage

See full
Return on equity67%+15.8pp
Debt / equity3.1×+1.6×
Current ratio3.2×+1.4×

Where this comes from

Reported directly by Zoetis in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Zoetis’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zoetis's other pharmaceutical — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Zoetis's other pharmaceutical — revenue?
Zoetis (ZTS) reported other pharmaceutical — revenue of $158M in Q1 2026.
How has Zoetis's other pharmaceutical — revenue changed year-over-year?
Zoetis's other pharmaceutical — revenue decreased by 0.0% year-over-year, from $158M to $158M.
What is the long-term trend for Zoetis's other pharmaceutical — revenue?
Over 3 years (2021 to 2025), Zoetis's other pharmaceutical — revenue has grown at a -10.4% compound annual growth rate (CAGR), from $966M to $696M.
What does other pharmaceutical — revenue mean?
This metric represents the total revenue generated from the sale of pharmaceutical products that fall outside of the company's primary categories, such as vaccines, parasiticides, or anti-infectives. It captures specialized therapeutic offerings, diagnostic tools, or niche health solutions that contribute to the company's diversified animal health portfolio. This segment is essential for understanding the breadth of the company's product ecosystem beyond its core high-volume offerings.